SENS Senseonics Holdings Inc

$SENS partnership with $BBNX is a great way to further the integration with AID, though granted BBNX is a smaller player than those incumbents.

$SENS hmmmm, just for fun i wonder how clowe i’ll be. 9.27 by tomorrow, 9.65 thurs, 10 by friday.

$SENS the common denominator for all incumbent AID players is the poor CGMs currently in use, they are two weeks disposable and much less accurate, much inferior experience comparing with Eversense 365. I think those AID users are crying for reliable, accurate, long term provider of CGM experience. Eversense 365 is filling this huge gap. Will Medtronic, Insulet, Abbot, Tandem pivot to Eversense 365 so that their users can focus more on their lifestyle than technology tinkering?

$SENS bears said don’t but after RS, yet anyone who bought after is up on all shares added since Oct 17 (recent run to 10 excluded). I’ve been consistently adding since, more than doubling my main account from 1000 (20k presplit) to 2400 shares. By no means am I a big investor but as time passes i only become more bullish as my thesis continues to play out until i reassess end of 2027. i cautioned against buying like 2 weeks ago as the price action wasnt looking particularly strong, when to add is important. All that said, I’m fairly confident that moving forward anything under 9 is an extremely safe buy and will be acting accordingly. Important to note, my main account had an avg of just over 6$ so everything from here for me is averaging up. I’ll post my TA read probably early next week to see how OPEx plays out first but things are looking good with this recent backtest.

$SENS FWIW & FYI: I just listened to part of the Senate hearings for the potential confirmation of Heidi Overton, MD, PhD (& Surgeon) as the new FDA Commissioner. Dr. Overton stated she has "Adult Onset Type One Diabetes". If confirmed the Diabetic community will now have someone who is a T1D that obviously understands the challenges that all Diabetics face. Hopefully she will expedite approvals of new meds and products such as the now available E365 - then Gemini & Freedom - and related AID pump systems to assist in everyday living for this community. Best wishes for her health & confirmation. GLTA Longs...

$SENS the common denominator for all pump vendors is the reliable, accurate, long lasting CGM, Eversense 365 and its future versions are filling this void. The market or diabetes community are crying out loud for it so that they do not have to change the shoddy CGMs they have to live with. The time is almost now.

$SENS Senseonics is accelerating into a pivotal new phase of growth. With Eversense 365, the world’s first & only one-year continuous glucose monitoring system, now approved and launched across Europe, Senseonics has expanded its commercial presence beyond the United States into Germany, Italy, Spain, and Sweden, while bringing its European sales and marketing operations in-house. The company delivered record Q2 2026 performance, generating $14.5 million in revenue, up approximately 120% year over year, with gross margin reaching approximately 59% & full-year revenue guidance raised to $62–66 million. U.S. revenue surged more than 150%, quarterly shipments reached an all-time high, active prescribers grew approximately 130%, & Eon Care surpassed 90 nurses. With broader European rollout, tender opportunities, automated insulin-delivery compatibility, and the Gemini and Freedom programs ahead, Senseonics is building momentum toward a more connected, global future in diabetes care.

$SENS Part One - Continued as Part two in the attached comment section: Just some admitedly anecdotal thoughts from a 3 year Senior Citizen LTH: Spouse was finally implanted with the E365 in late August after having to wait for over one year due to unrelated cardiac issues. The EON Care NP inserter did an Excellent job with both the insertion and related educational materials. I witnessed the insertion - which the spouse said was painless and only took several minutes. She is now in the transition period of about two weeks and everything is proceeding well. She is very happy to date that she switched from her Dexcom G6 CGM. The G6 has been incorrect over 100 points at times. Inserter also indicated that the number of insertions is rising appreciably over the last several months. She still has the Tandem T2 Slim pump which she likes but does not connect currently with the E365. She is scheduled to hopefully try the Twiist pump with a new Endo group MD in early October. Continued...

$SENS The Golden Cross formed with both the 50-day MA and the 200-day MA both curling up as it happened. Very bullish TA signal. Requires $11.29 for strong confirmation of the Golden Cross. Q3 GP contribution is going to make heads turn. Q3 results are going to be blockbuster. SENS knew this at the time of the last conference call. $11.29 is within reach in Q4, after the Q3 earnings call. When SP reaches $11.29 signalling strong confirmation, and I believe it will; Q4 is a near certainty of continuing momentum after Q3 earnings is announced. it will take until after the Q3 2028 earnings call for the "Street" to begin evaluating SENS on future profits. That's when the fun begins. Many have been holding for 5 years or more. Hang in there, you will win.

$SENS Just picked up 462 more shares. Holding 9564 shares, so close to 10k. They will raise full year guidance yet again this upcoming ER. Eversense 365 is most likely selling like hotcakes in the EU. The Germans are well known for precision manufacturing, and Eversense 365 is ahead of competition by miles with its accuracy.

$SENS Dexcom MC is $33B if we got to just 10% of that the sare price would be $60+... They have some work to do to get there but it is, at minimum, a feasible goal.

$SENS i was gonna do a TA post next week sometime but its pretty straight forward. recent price action since tapping 10 was a backtest for short term MAs, falling below a large number of them including the 10 DMA back on sept 8. today we are officially above all moving averages with the exception of 200 WMA currently at 11.05. that’s presplit .55. I really don’t see what stops this from squeezing if we break and hold above that.

$SENS I have $2900 USD ready to pull the trigger to buy more if shorts try anything funny. I think Tandem-Senseonics partnership news is next!

$SENS Bought 1 share to track price. This is screaming BUY but we are bearish above $6.33 because we want cheap shares. Pump integration is here, please dip below $6...

$SENS 2nd day this week, head fake, show green in pre-market with a big jump; sucks people in via social media, then pull the rug.

$SENS I thought to myself, soon as I’m even I’m selling up. I’ve had multiple chances, even as I type this. It’s trying to hard to push 10.5, once it does 11+ will fly

$SENS That wasn't exactly the close that I was hoping for, but it's green. Green is good!

$SENS Shit I was being cheap the other day and wanted to buy the lowest share price. I should've slapped the ask 😢

$SENS holding calls for 12.5 in January and they are looking scrumptious. Will prolly sell when we get to 11.80 📈🔥

$SENS Compelled to respond to the forum. Love challenges. A squeeze would require more than high short interest: a strong catalyst, rapid price appreciation on much heavier volume, and continued higher short interest with tightening borrow availability. Because SENS was heavily shorted around the post-split equivalent of ~$20, many older shorts remain highly profitable despite this rally. Pressure will increase as SENS approaches the mid-to-upper teens, with ~$20–$25 becoming a critical zone where older shorts approach breakeven or losses and newer shorts are already deeply underwater. Just draw a line from 2/25 to today for proof. Shorts are killing it. Shorts are also LTH’s & SENS has a proven track record of their wet dream. A sustained move through the area I mentioned on heavy volume is the only thing that would accelerate covering, We remain at a remote possiblity of a short squeeze & I couldn’t care less. The tech will win, despite E-level governance incompetence.